Parabolan 100

Parabolan 100 Dragon Pharma — Overview

Parabolan 100 Dragon Pharma is trenbolone hexahydrobenzylcarbonate at 100 mg/ml — the long-ester injectable form of trenbolone and the only trenbolone variant that was ever approved for human clinical use, marketed originally under the Parabolan trade name by Negma Laboratories in France until its discontinuation in 1997. The hexahydrobenzylcarbonate ester produces a half-life of approximately 14 days, enabling once- or twice-weekly injection schedules that distinguish it from trenbolone acetate (injected every other day) and trenbolone enanthate (injected twice weekly at a comparable dosing interval). The active compound is identical across all trenbolone esters: a modified 19-nortestosterone derivative with anabolic and androgenic ratings each approximately five times that of testosterone.

Trenbolone does not aromatize — it lacks the C19 methyl group and the structural features required for aromatase activity. The result is a dry, hard anabolic environment with no estrogenic water retention and no gynecomastia from the aromatase pathway. Despite this, trenbolone carries strong progestogenic activity as a 19-nor compound; prolactin management is part of any trenbolone protocol. The combination of extreme anabolic potency, zero aromatization, severe androgenic activity, and a 14-day ester makes Parabolan 100 the practical choice for experienced users who want tren's effect profile with a manageable injection schedule. Available at Steroid Warehouse as a 100 mg/ml oil solution, Parabolan 100 is one of the most demanding and effective compounds in injectable AAS use.

About the Compound: Trenbolone Hexahydrobenzylcarbonate

Trenbolone hexahydrobenzylcarbonate is a synthetic 19-nortestosterone derivative — the C19-methyl group is absent, which is the structural basis for both its reduced androgenic-to-estrogenic conversion profile and its progestogenic receptor activity. Unlike nandrolone (the other major 19-nor AAS), trenbolone does not undergo 5α-reductase conversion to a weaker metabolite. Nandrolone converts to dihydronandrolone (DHN), a weak androgen; trenbolone instead resists enzymatic reduction and remains active at androgen receptors in all tissues at its full potency. This means finasteride and dutasteride have no protective effect against trenbolone's androgenic activity at the scalp, skin, or prostate.

Trenbolone's binding affinity for the androgen receptor is approximately five times that of testosterone. It also binds the glucocorticoid receptor (antagonizing cortisol) and the progesterone receptor (the source of prolactin elevation risk). These three receptor interactions simultaneously account for its extreme anti-catabolic effect, its characteristic CNS stimulatory profile (night sweats, insomnia, anxiety, aggression), and its progestogenic side effect potential. Trenbolone does not aromatize under any conditions — it lacks the C19 group and the C4–5 double bond required for aromatase interaction.

The hexahydrobenzylcarbonate ester (also called cyclohexylmethylcarbonate) is the largest and slowest of the three commercially available trenbolone esters. The approximate half-life of 14 days enables a once- or twice-weekly injection schedule with stable blood levels maintained throughout the cycle. This ester was the one used in the original Parabolan product and remains the only trenbolone variant that has a history of formal human clinical use. At 100 mg/ml, Parabolan 100 Dragon Pharma delivers 100 mg of ester-attached trenbolone per ml; the free trenbolone yield after ester hydrolysis is approximately 72 mg per 100 mg of ester-bound compound (hexahydrobenzylcarbonate molecular weight reduction factor).

What Parabolan Does

• Extreme strength and neuromuscular output increase — trenbolone produces strength gains that exceed what its direct anabolic mass effect alone would predict; the combination of high androgen receptor binding affinity, glucocorticoid antagonism (anti-cortisol), and CNS stimulation creates a training environment where recovery accelerates, strength climbs rapidly, and muscular output per session improves dramatically; users commonly report strength increases within the first 2–3 weeks that compress months of natural progression into weeks
• Lean, dry mass accumulation with zero water retention — the complete absence of aromatization means no estrogenic water retention; every pound gained on a trenbolone cycle reflects lean tissue or glycogen without subcutaneous fluid; the result is a dense, hard, vascular appearance that distinguishes trenbolone mass from the fuller, softer look of aromatizing compounds; this makes Parabolan applicable across both bulking and competition-prep phases depending on caloric context
• Extreme nitrogen retention and anti-catabolic protection — trenbolone's glucocorticoid receptor antagonism directly suppresses cortisol-mediated muscle breakdown; combined with the high anabolic receptor binding, nitrogen retention is strongly positive; users in caloric deficits retain significantly more lean tissue than they would without trenbolone; this property makes it uniquely valuable in cutting phases where muscle preservation under caloric restriction is the primary objective
• Fat oxidation enhancement — trenbolone exhibits direct partitioning effects that preferentially direct nutrients toward muscle tissue and away from fat storage; the androgenic environment increases metabolic rate; these effects combine to produce body composition improvements even without dramatic changes in caloric intake, making trenbolone one of the most effective recomposition compounds available
• Vascularity and muscle density — the combination of zero aromatization, strong androgen receptor activation at muscle tissue, and reduced subcutaneous water creates pronounced vascularity and muscle density; these cosmetic properties are especially pronounced in the final weeks of a cycle as body fat decreases; the "Parabolan look" — hard, striated, highly vascular — is one of the compound's most recognized characteristics among advanced users

Who It's For

• Experienced AAS users with prior trenbolone or 19-nor exposure — Parabolan is not appropriate for users without prior AAS experience; the combination of powerful androgenic, progestogenic, and CNS effects requires a baseline understanding of how the user's body responds to trenbolone-class compounds; users who have completed at least one cycle of Trenbolone Acetate and understand their individual tolerance to tren's CNS effects, androgenic profile, and prolactin response are the appropriate starting point; the 14-day half-life of the hexahydrobenzylcarbonate ester means side effects cannot be rapidly eliminated by stopping injections — unlike acetate where clearance occurs in 3–5 days
• Users in lean mass, recomposition, or competition-prep phases — the specific scenario where Parabolan outperforms most alternatives is a 10–12 week phase where lean tissue gain, fat loss, strength increase, and body composition improvement are all required simultaneously; the dry, hard gains without water retention make it suitable for pre-competition protocols; the anti-catabolic glucocorticoid antagonism makes it valuable in caloric deficits; the ester's half-life allows stable management without daily injections
• What differentiates this from similar alternatives: compared to Trenbolone Acetate, Parabolan produces identical pharmacological effects from the same active compound but with a 14-day half-life enabling less frequent injection and slower, more stable blood level curves; the trade-off is that side effects, if they develop, persist longer after stopping; compared to Trenbolone Enanthate, Parabolan has a moderately longer half-life and marginally higher ester molecular weight (lower free trenbolone yield per mg), but the clinical difference is minimal; compared to Oral Tren (methyltrienolone), Parabolan is injectable with no 17α-alkylation and therefore substantially less hepatotoxic — the appropriate format for cycle durations beyond 4–6 weeks
• Users who should choose something else: anyone encountering trenbolone for the first time should begin with Trenbolone Acetate rather than Parabolan — acetate's short half-life allows dose reduction or cessation with rapid side-effect resolution if tolerance is poor; users with baseline cardiovascular risk, elevated blood pressure, or poor lipid profiles should not run trenbolone in any ester; users sensitive to night sweats, insomnia, or anxiety from previous trenbolone experience should consider whether the extended half-life of Parabolan suits their situation

Parabolan vs Alternatives

Combinations

Side Effects & Management

Bloodwork Monitoring

PCT

The hexahydrobenzylcarbonate ester's 14-day half-life means Parabolan takes approximately 3–4 weeks to clear to a level where PCT can begin effectively. The standard rule: PCT begins 3 weeks after the last Parabolan injection. For cycles using Parabolan alongside a long-ester testosterone (Enantat 250 or Cypionat 250), both compounds have similar clearance timelines, so the 3-week wait covers both. Confirm that prolactin has normalized before starting PCT — elevated prolactin during PCT impairs HPTA recovery.

Practical Summary

References